The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD ...

The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona this weekend – ...

Indeed, the global oncology community trusts ESMO to disseminate the latest results of cancer research. Why? Because it is ...

In the study, MILTON was used to analyse 3,200 diseases and achieved a high prediction score for 1,091 of them. It can be ...

It's known that excessive use of earbuds at high volumes can cause hearing loss, so somewhat ironic that the FDA has just ...

The $25 million award from the Advanced Research Projects Agency for Health (ARPA-H) will be used to develop Cellino's NEBULA ...

Olorofim is licensed in Europe and Asia to Japanese pharma Shionogi, which paid $100 million upfront for rights to the drug ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of ...

GSK has abandoned its clinical-stage vaccine for herpes simplex virus (HSV) after a disappointing phase 1/2 trial, ceding the ...

UK biotech F2G has raised $100 million as it prepares to refile its olorofim candidate for invasive fungal infections, which ...

The PM Society Digital Awards 2024, an annual event in the healthcare marketing industry sponsored by Twist Health, held its ...

The facility at a business park in Raheen, Limerick, was first announced in 2022 and this is the second time that Lilly has ...